Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Profit After Tax (2020 - 2025)

Historic Profit After Tax for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$12.6 million.

  • Tarsus Pharmaceuticals' Profit After Tax rose 4626.39% to -$12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.2 million, marking a year-over-year increase of 3958.9%. This contributed to the annual value of -$115.6 million for FY2024, which is 1496.69% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Profit After Tax stood at -$12.6 million, which was up 4626.39% from -$20.3 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Profit After Tax registered a high of $10.4 million during Q1 2021, and its lowest value of -$41.9 million during Q4 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' median Profit After Tax value was -$22.5 million (recorded in 2022), while the average stood at -$20.3 million.
  • In the last 5 years, Tarsus Pharmaceuticals' Profit After Tax soared by 63019.93% in 2021 and then crashed by 44717.05% in 2023.
  • Tarsus Pharmaceuticals' Profit After Tax (Quarter) stood at -$14.9 million in 2021, then grew by 8.43% to -$13.6 million in 2022, then crashed by 208.13% to -$41.9 million in 2023, then soared by 44.84% to -$23.1 million in 2024, then surged by 45.55% to -$12.6 million in 2025.
  • Its last three reported values are -$12.6 million in Q3 2025, -$20.3 million for Q2 2025, and -$25.1 million during Q1 2025.